ribociclib

ribociclib is a targeted therapy medication used in the treatment of certain advanced breast cancers. It is a cyclin-dependent kinase inhibitor, specifically blocking the activity of CDK4 and CDK6, which are proteins involved in cell cycle progression. Developed by Novartis, it is marketed under the brand name Kisqali and is typically used in combination with other endocrine therapies.

Medical uses

Ribociclib is approved by the U.S. Food and Drug Administration and the European Medicines Agency for use in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is also approved in combination with fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer as initial endocrine-based therapy or following disease progression on endocrine therapy. The approvals were based on pivotal clinical trials such as MONALEESA-2, MONALEESA-3, and MONALEESA-7, which demonstrated significant improvement in progression-free survival. Its use is guided by specific diagnostic testing to confirm the hormone receptor status of the tumor.

Adverse effects

Common adverse effects associated with ribociclib include neutropenia, nausea, fatigue, diarrhea, leukopenia, alopecia, vomiting, constipation, headache, and back pain. Serious adverse effects can include QT prolongation, which requires monitoring via electrocardiogram, severe neutropenia, hepatotoxicity, and interstitial lung disease. Management often involves dose interruptions, reductions, or discontinuation as outlined in the prescribing information from Novartis. Patients are typically monitored with regular complete blood counts and assessments of liver function tests.

Pharmacology

Ribociclib functions as a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. These kinases, when activated by D-type cyclins, promote cell cycle progression from the G1 phase to the S phase by phosphorylating and inactivating the retinoblastoma protein. By inhibiting this pathway, ribociclib induces G1 phase arrest, suppressing cellular proliferation in cancer cells that are dependent on this signaling. Pharmacokinetically, it is administered orally and undergoes metabolism primarily via the CYP3A4 enzyme system in the liver, necessitating caution with concomitant use of strong CYP3A inhibitors or inducers.

History

Ribociclib was discovered and developed by the Novartis Institutes for BioMedical Research. It received its first global approval from the U.S. Food and Drug Administration in March 2017 based on data from the MONALEESA-2 trial. Subsequent approvals from the European Medicines Agency and other regulatory agencies worldwide followed. The development program, including the MONALEESA clinical trial series, was a significant effort in oncology research, building upon earlier work on cell cycle inhibitors like palbociclib from Pfizer.

Society and culture

Marketed as Kisqali by Novartis, ribociclib has had a substantial impact on the treatment landscape for HR-positive breast cancer. Its cost and access have been subjects of discussion within healthcare systems like the National Health Service in the United Kingdom and among insurers in the United States. The drug has been featured in presentations at major medical conferences such as the American Society of Clinical Oncology and the San Antonio Breast Cancer Symposium. Its development story is often cited in discussions about the evolution of targeted therapies in oncology following the precedent set by drugs like trastuzumab for HER2-positive breast cancer. Category:Antineoplastic drugs Category:Cyclin-dependent kinase inhibitors Category:Novartis brands